Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
Phase 2 Unknown
25 enrolled
VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
Phase 2 Unknown
85 enrolled
Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer
Phase 3 Unknown
80 enrolled
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Unknown
180 enrolled
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
Phase 2 Unknown
52 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
Phase NA Unknown
35 enrolled
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission
Phase 3 Unknown
244 enrolled
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
Phase 3 Unknown
2,000 enrolled
Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Unknown
25 enrolled
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Unknown
800 enrolled
Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia
Phase 2 Unknown
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia
Phase 3 Unknown
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
1,000 enrolled
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Unknown
PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
Phase 2 Unknown
16 enrolled
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
Phase 3 Unknown
1,800 enrolled
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
Phase 2 Unknown
25 enrolled
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia
Phase 3 Unknown
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase NA Unknown
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphocytic Leukemia
Phase 2/3 Unknown
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
Phase 3 Unknown
750 enrolled
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Phase 3 Unknown
400 enrolled
Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
Phase 1 Unknown
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Phase 2 Unknown
80 enrolled
Polyvinylpyrrolidone-Sodium Hyaluronate Gel in Reducing Pain From Oral Mucositis in Young Patients With Cancer
Phase NA Unknown
50 enrolled
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
Phase 2 Unknown
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
Phase 1/2 Unknown
60 enrolled
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
Phase 3 Unknown
Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia
Phase 1 Unknown
21 enrolled
Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase NA Unknown
550 enrolled
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
Phase NA Unknown
200 enrolled
Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant
Unknown
125 enrolled
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 2 Unknown
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
750 enrolled
Biomarkers in Samples From Adult Patients With Acute Myeloid Leukemia Who Failed Existing Standard-of-Care Treatment
Unknown
400 enrolled
Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia
Unknown
400 enrolled
Study of Long-Term Outcomes of Patients With Acute Lymphoblastic Leukemia Who Were Enrolled as Children on Clinical Trials EORTC-58741, EORTC-58831, EORTC-58832, or EORTC-58881 Between 1971 and 1998
Unknown
3,138 enrolled
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
Phase 2 Unknown
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Phase 3 Unknown
80 enrolled
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
Phase 3 Unknown
220 enrolled
Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors
Phase 1 Unknown
15 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia
Phase 3 Unknown
1,520 enrolled
Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Phase 3 Unknown
2,000 enrolled
Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia
Phase 3 Unknown
4,000 enrolled
Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Unknown
200 enrolled
Radiolabeled Monoclonal Antibody, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory B-Cell Cancer
Phase 1 Unknown